Literature DB >> 11508670

A fulminant hepatic failure model in the rat: involvement of interleukin-1beta and tumor necrosis factor-alpha.

M Shito1, U J Balis, R G Tompkins, M L Yarmush, M Toner.   

Abstract

The development of a fulminant hepatic failure (FHF) model is necessary for evaluating the efficacy of extracorporeal liver support systems. Recognizing the multifaceted functions of the liver, including synthesis and degradation, we investigated blood chemistry, histological findings, and survival rate in D-galactosamine (GalN)-intoxicated rats. The pathophysiologic response of inflammatory cytokines, interleukin-1beta (IL-1beta) and tumor necrosis factor-alpha (TNF-alpha), was also measured. Sprague-Dawley rats (200-300 g) were divided into two groups: GalN and saline injection. Rats were killed at 1, 3, 6, 12, 24, 36, 48, 72, and 168 hr after intraperitoneal injection of GalN (1.4 g/kg) or saline. In both groups, liver-specific markers, liver histology, and IL-1beta and TNF-alpha levels in blood and liver tissue were analyzed. In a second series of experiments, the survival rates were examined after two administrations of GalN at 1.0, 1.4 or 2.0 g/kg, at a 12-hr interval. In the GalN injection group, the liver-specific markers reached peak levels between 36 and 48 hr after injection. Histologically, hepatocellular necrosis was seen at 6-48 hr, followed by a regenerative phase occurring between 72 and 168 hr. IL-1beta and TNF-alpha levels in liver tissue peaked at 12 hr and 1 hr, respectively. The levels of these cytokines in blood, however, did not change significantly. The survival rates at day 7 for 1.0, 1.4 or 2.0 g/kg GalN injected twice were 77.8%, 16.7%, and 0%, respectively. These results suggest that single and double injection of GalN enable the development of reversible and irreversible FHF models. The results also indicate that IL-1beta and TNF-alpha are useful markers of liver injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11508670     DOI: 10.1023/a:1010653504568

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  32 in total

1.  Migration of neutrophils across endothelial monolayers is stimulated by treatment of the monolayers with interleukin-1 or tumor necrosis factor-alpha.

Authors:  M B Furie; D D McHugh
Journal:  J Immunol       Date:  1989-11-15       Impact factor: 5.422

2.  A dog model for acetaminophen-induced fulminant hepatic failure.

Authors:  A Francavilla; L Makowka; L Polimeno; M Barone; J Demetris; J Prelich; D H Van Thiel; T E Starzl
Journal:  Gastroenterology       Date:  1989-02       Impact factor: 22.682

3.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.

Authors:  F D Watanabe; C J Mullon; W R Hewitt; N Arkadopoulos; E Kahaku; S Eguchi; T Khalili; W Arnaout; C R Shackleton; J Rozga; B Solomon; A A Demetriou
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

4.  Effects of putrescine on D-galactosamine-induced acute liver failure in rats.

Authors:  S Nishiguchi; T Kuroki; T Takeda; S Nakajima; S Shiomi; S Seki; I Matsui-Yuasa; S Otani; K Kobayashi
Journal:  Hepatology       Date:  1990-08       Impact factor: 17.425

5.  An improved model of galactosamine-induced fulminant hepatic failure in the pig.

Authors:  K Kalpana; H S Ong; K C Soo; S Y Tan; J Prema Raj
Journal:  J Surg Res       Date:  1999-04       Impact factor: 2.192

6.  Reversal of experimental acute hepatic failure in the rat.

Authors:  L Makowka; R E Falk; L E Rotstein; J A Falk; N Nossal; B Langer; L M Blendis; M J Phillips
Journal:  J Surg Res       Date:  1980-12       Impact factor: 2.192

7.  Biochemical, hematological and histological changes in a fulminant hepatic failure rat model for artificial liver assessment.

Authors:  E Chirito; C Lister; T M Chang
Journal:  Artif Organs       Date:  1979-02       Impact factor: 3.094

8.  Impaired liver regeneration in inducible nitric oxide synthasedeficient mice.

Authors:  R M Rai; F Y Lee; A Rosen; S Q Yang; H Z Lin; A Koteish; F Y Liew; C Zaragoza; C Lowenstein; A M Diehl
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-10       Impact factor: 11.205

9.  Tumor necrosis factor-induced hepatic DNA fragmentation as an early marker of T cell-dependent liver injury in mice.

Authors:  F Gantner; M Leist; S Jilg; P G Germann; M A Freudenberg; G Tiegs
Journal:  Gastroenterology       Date:  1995-07       Impact factor: 22.682

10.  Interleukin-1 and nitric oxide protect against tumor necrosis factor alpha-induced liver injury through distinct pathways.

Authors:  I Bohlinger; M Leist; J Barsig; S Uhlig; G Tiegs; A Wendel
Journal:  Hepatology       Date:  1995-12       Impact factor: 17.425

View more
  17 in total

1.  Effects of hemoperfusion adsorption and/or plasma exchange in treatment of severe viral hepatitis: a comparative study.

Authors:  Nian-Hai He; Ying-Jie Wang; Ze-Wen Wang; Jun Liu; Jia-Jia Li; Guo-Dong Liu; Yu-Ming Wang
Journal:  World J Gastroenterol       Date:  2004-04-15       Impact factor: 5.742

2.  Treatment of fulminant hepatic failure in rats using a bioartificial liver device containing porcine hepatocytes producing interleukin-1 receptor antagonist.

Authors:  Masahiro Shinoda; Arno W Tilles; Go Wakabayashi; Atsushi Takayanagi; Hirohisa Harada; Hideaki Obara; Kazuhiro Suganuma; François Berthiaume; Motohide Shimazu; Nobuyoshi Shimizu; Masaki Kitajima; Ronald G Tompkins; Mehmet Toner; Martin L Yarmush
Journal:  Tissue Eng       Date:  2006-05

3.  Transplantation of microencapsulated umbilical-cord-blood-derived hepatic-like cells for treatment of hepatic failure.

Authors:  Fang-Ting Zhang; Hui-Juan Wan; Ming-Hua Li; Jing Ye; Mei-Jun Yin; Chun-Qiao Huang; Jie Yu
Journal:  World J Gastroenterol       Date:  2011-02-21       Impact factor: 5.742

4.  A bioartificial liver device secreting interleukin-1 receptor antagonist for the treatment of hepatic failure in rats.

Authors:  Masahiro Shinoda; Arno W Tilles; Naoya Kobayashi; Go Wakabayashi; Atsushi Takayanagi; Toshinori Totsugawa; Hirohisa Harada; Hideaki Obara; Kazuhiro Suganuma; François Berthiaume; Motohide Shimazu; Nobuyoshi Shimizu; Noriaki Tanaka; Masaki Kitajima; Ronald G Tompkins; Mehmet Toner; Martin L Yarmush
Journal:  J Surg Res       Date:  2006-11-01       Impact factor: 2.192

5.  Impaired gluconeogenesis in a porcine model of paracetamol induced acute liver failure.

Authors:  Konstantinos J Dabos; Henry R Whalen; Philip N Newsome; John A Parkinson; Neil C Henderson; Ian H Sadler; Peter C Hayes; John N Plevris
Journal:  World J Gastroenterol       Date:  2011-03-21       Impact factor: 5.742

6.  FR167653 attenuates murine immunological liver injury.

Authors:  Hong-Wei Yao; Jun Li; Ji-Qiang Chen
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

7.  Ethyl pyruvate protects against experimental acute-on-chronic liver failure in rats.

Authors:  Lu-Wen Wang; Li-Kun Wang; Hui Chen; Cheng Fan; Xun Li; Can-Ming He; Zuo-Jiong Gong
Journal:  World J Gastroenterol       Date:  2012-10-28       Impact factor: 5.742

8.  A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells.

Authors:  Hong Wei Yao; Jun Li; Ji Qiang Chen; Shu Yun Xu
Journal:  Inflammation       Date:  2004-04       Impact factor: 4.092

9.  Changes of gut flora and endotoxin in rats with D-galactosamine-induced acute liver failure.

Authors:  Lan-Juan Li; Zhong-Wen Wu; Dang-Sheng Xiao; Ji-Fang Sheng
Journal:  World J Gastroenterol       Date:  2004-07-15       Impact factor: 5.742

10.  Assessment of resin perfusion in hepatic failure in vitro and in vivo.

Authors:  Ying-Jie Wang; Ze-Wen Wang; Bing-Wei Luo; Hong-Ling Liu; Hong-Wei Wen
Journal:  World J Gastroenterol       Date:  2004-03-15       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.